Investigations in systemic vasculitis. The role of the laboratory

被引:7
|
作者
Csernok, Elena [1 ]
Bossuyt, Xavier [2 ,3 ]
机构
[1] Vasculitis Ctr Tubingen Kirchheim, Dept Internal Med Rheumatol & Immunol, Kirchheim unter Teck, Germany
[2] Katholieke Univ Leuven, Dept Microbiol & Immunol, Leuven, Belgium
[3] Univ Hosp Leuven, Dept Lab Med, Leuven, Belgium
来源
关键词
ANCA; Systemic vasculitis; Laboratory investigation; Antigen-specific immunoassays; Immunofluorescence; Consensus recommendations; ANCA-ASSOCIATED VASCULITIS; C-REACTIVE PROTEIN; INTERNATIONAL CONSENSUS; CLINICAL UTILITY; DISEASE-ACTIVITY; FOLLOW-UP; COMPLEMENT; ANTIBODIES; GRANULOMATOSIS; RELAPSE;
D O I
10.1016/j.berh.2018.07.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The diagnosis of systemic vasculitis is challenging. Laboratory testing may provide useful information. Routine laboratory tests include erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), blood count, serum creatinine, urinalysis, specific autoantibodies, complement, immunoglobulin, cryoglobulin, and Hepatitis B and C serology. Although ESR and CRP are often helpful for the diagnosis of vasculitis, they are nonspecific and do not help in distinguishing between vasculitis disease activity and a concomitant infection or another source of inflammation. A few autoantibodies are helpful for diagnosis, such as anti-neutrophil cytoplasmic antibodies (ANCAs) (in ANCA-associated small-vessel vasculitis), anti-glomerular basement membrane (GBM) antibodies (in anti-GBM antibody disease), and anti-C1q antibodies (in immune complex-associated small-vessel vasculitis). The 2017 revised consensus recommendations on ANCA testing state that high quality antigen-specific immunoassays are the preferred screening methodology for the diagnosis of ANCA-associated vasculitis. ANCA subtypes (proteinase-3-ANCA and myeloperoxidase-ANCA) are associated with different epidemiological, genetic, and clinical features. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:52 / 62
页数:11
相关论文
共 50 条
  • [1] Systemic vasculitis.
    Planchon, B
    Cassagnau, E
    Pottier, P
    Pistorius, MA
    JOURNAL DES MALADIES VASCULAIRES, 2000, 25 (03) : 166 - 174
  • [2] Sarcoidosis and systemic vasculitis.
    Fernandes, SRM
    Singsen, BH
    Hoffman, GS
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S371 - S371
  • [3] Epidemiology of systemic vasculitis.
    Lane S.E.
    Watts R.
    Scott D.G.
    Current Rheumatology Reports, 2005, 7 (4) : 270 - 275
  • [4] Investigations in systemic vasculitis - The role of imaging
    Schmidt, Wolfgang A.
    Blockmans, Daniel
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2018, 32 (01): : 63 - 82
  • [5] Neurological manifestations of systemic necrotizing vasculitis.
    Said, G
    REVUE NEUROLOGIQUE, 2002, 158 (10) : 915 - 918
  • [6] The vasculitis damage index as a surrogate outcome measure in systemic vasculitis.
    McRorie, ER
    McGill, A
    Plant, W
    Fleming, S
    Adams, W
    Craig, K
    Luqmani, RA
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 829 - 829
  • [7] Investigations in systemic vasculitis - The role of renal pathology
    Berden, Annelies E.
    Trejo, Maria A. C. Wester
    Bajema, Ingeborg M.
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2018, 32 (01): : 83 - 93
  • [8] The use of infliximab in systemic vasculitis. A case series
    Shergy, WJ
    Hernandez, J
    Calamia, K
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 320 - 320
  • [9] The Antiphospholipid syndrome contributes to damage in patients with systemic vasculitis.
    Moco, R
    Oliveri, C
    Ferreira, S
    Antunes, M
    Khamashta, MA
    Hughes, GRV
    D'Cruz, DP
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S651 - S651
  • [10] Validity of a disease activity index for systemic necrotizing vasculitis.
    Whiting-O'Keefe, WE
    Stone, JH
    Hellmann, DB
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S317 - S317